Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NARecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions
Venous Thromboembolism
Interventions
BEHAVIORAL

Electronic alert

"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Portola Pharmaceuticals

INDUSTRY

lead

Brigham and Women's Hospital

OTHER